Stock Analysis

Asian Companies Estimated Below Fair Value In October 2025

In October 2025, Asian markets are navigating a complex landscape marked by mixed economic signals and evolving monetary policies. As investors seek opportunities in this environment, identifying stocks that appear undervalued can be a strategic approach to potentially capitalize on market inefficiencies.

Advertisement

Top 10 Undervalued Stocks Based On Cash Flows In Asia

NameCurrent PriceFair Value (Est)Discount (Est)
Xiamen Amoytop Biotech (SHSE:688278)CN¥84.05CN¥165.0949.1%
Tibet GaoZheng Explosive (SZSE:002827)CN¥38.57CN¥76.7249.7%
Takara Bio (TSE:4974)¥953.00¥1829.4647.9%
Samyang Foods (KOSE:A003230)₩1509000.00₩3006664.2249.8%
Malee Group (SET:MALEE)THB5.60THB11.0149.1%
freee K.K (TSE:4478)¥3270.00¥6517.3249.8%
Devsisters (KOSDAQ:A194480)₩48200.00₩95922.4049.8%
Dajin Heavy IndustryLtd (SZSE:002487)CN¥47.21CN¥90.8548%
Com2uS (KOSDAQ:A078340)₩36500.00₩70061.6247.9%
Aecc Aero Science and TechnologyLtd (SHSE:600391)CN¥28.43CN¥54.7748.1%

Click here to see the full list of 279 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.

Let's review some notable picks from our screened stocks.

SK Biopharmaceuticals (KOSE:A326030)

Overview: SK Biopharmaceuticals Co., Ltd. is a pharmaceutical company focused on researching and developing drugs for central nervous system disorders, with a market cap of ₩8.14 trillion.

Operations: The company generates revenue primarily from its New Pharmaceutical Business segment, amounting to ₩620.28 million.

Estimated Discount To Fair Value: 45.2%

SK Biopharmaceuticals is trading at ₩104,000, significantly below its estimated fair value of ₩189,933.83. Despite earnings growth being slower than the market average, revenue is expected to grow 23.4% annually—outpacing the KR market's 7.6%. The stock is undervalued by over 20%, and its Return on Equity is projected to reach a robust 30.5% in three years, indicating strong future profitability potential despite high non-cash earnings levels.

KOSE:A326030 Discounted Cash Flow as at Oct 2025
KOSE:A326030 Discounted Cash Flow as at Oct 2025

Tianqi Lithium (SZSE:002466)

Overview: Tianqi Lithium Corporation engages in the investment, production, processing, extraction, and sale of lithium and lithium compounds across Australia, Chile, and China with a market capitalization of approximately CN¥77.75 billion.

Operations: Tianqi Lithium generates revenue through the investment, production, processing, extraction, and sale of lithium products and compounds in Australia, Chile, and China.

Estimated Discount To Fair Value: 41.6%

Tianqi Lithium is trading at CN¥47.57, significantly below its estimated fair value of CN¥81.48, suggesting it may be undervalued based on cash flows. Despite a decline in sales to CN¥4.82 billion for H1 2025 from CN¥6.42 billion a year ago, the company turned profitable with net income of CN¥84.41 million compared to a significant loss previously. Revenue is forecasted to grow 16.1% annually, surpassing the broader Chinese market's growth rate.

SZSE:002466 Discounted Cash Flow as at Oct 2025
SZSE:002466 Discounted Cash Flow as at Oct 2025

Wiwynn (TWSE:6669)

Overview: Wiwynn Corporation is involved in the research, development, design, testing, and sales of semiconductor products and peripheral equipment globally, with a market cap of NT$643.94 billion.

Operations: The company's revenue is primarily derived from its Computer Hardware segment, totaling NT$604.83 billion.

Estimated Discount To Fair Value: 12.3%

Wiwynn, trading at NT$3465, is below its estimated fair value of NT$3952.5, potentially indicating undervaluation based on cash flows. Recent earnings show significant growth with Q2 sales reaching NT$220.74 billion from NT$77.48 billion a year ago and net income rising to NT$12.12 billion from NT$4.69 billion previously. Despite high revenue growth forecasts of 23.8% annually, earnings are expected to grow slower than the Taiwan market average at 13.3%.

TWSE:6669 Discounted Cash Flow as at Oct 2025
TWSE:6669 Discounted Cash Flow as at Oct 2025

Turning Ideas Into Actions

Contemplating Other Strategies?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com